Stem Cell Clinic

Hemostemix Announces the Appointment of Timothy Chang to Board of Advisors – Yahoo Finance

By adminApril 22, 2020Stem Cell Treatment

Calgary, Alberta--(Newsfile Corp. - April 21, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Timothy C. Chang to its Board of Advisors.

Mr. Chang is currently a Private Investor and an investment committee member of an Asian-based hedge fund with average total AUM of approximately US$1 billion. He has also been a consultant to Newport Healthcare Advisors and to SSG Capital Management. Mr. Chang is a renowned private equity investor who has a track record of successful special situations and venture capital business investments throughout the Asian region.

Prior to becoming a Private Investor, Mr. Chang was a Managing Director of Citigroup Venture Capital International Asia Ltd., (CVCI) Hong Kong, 2005 - 2008, where he worked on and invested in private equity deals throughout Asia with a focus on Greater China. Prior to CVCI, from 2003 - 2005, Mr. Chang was Managing Director and Head of Greater China for Cerberus, a distressed assets private equity fund based in New York. Mr. Chang was also an Executive Director, Direct Investments and the Head of the Special Situations Group at AIG Investment Corp. Ltd., Hong Kong.

Timothy Chang graduated Harvard University, Cambridge, MA, Summa Cum Laude with a B.A. in Applied Mathematics and Economics. He completed his senior honors thesis (with Professor Jeffrey Sachs as his thesis advisor) researching and modeling the Predictability of Realignments in the European Monetary System.

"The company is commercializing ACP-01 to treat critical limb ischemia in Japan, South Korea, and across Asia," said Thomas Smeenk, President & CEO. "Timothy's foundation is Asia. His relationships are within its financing community. His business experience and knowledge of worthy license partners in the region will be very helpful, as we consummate an agreement wherein we retain scalable production, yet enable our partners to provide sales and distribution on an licensed indication basis," Smeenk said.

Timothy Chang reflected: "Despite slogging my way through pre-med classes in college like Organic Chemistry and working at a lab at the Harvard Medical School, I somehow forgot to submit my application to medical school. In the late 1970's and early 1980's there were limited opportunities for Chinese-Americans to excel on Wall Street, in U.S. politics or law, and in most non-science or non-engineering based fields. My "tiger mom" (who had endured the hardships of being a Chinese immigrant in the US in the 1950's) thus decided that medicine was the field for her eldest son. I saw things a little differently, rebelled, and decided to head to New York City and Wall Street to try to break new ground. Many years later, though, I have come to realize that I have never lost my love for math and science (especially the science behind medicine). It is thus with great delight that I now find myself in a position to help Hemostemix break new ground in the autologous stem cell therapies and regenerative medicine markets," Timothy stated.

ABOUT HEMOSTEMIX

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 500 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit http://www.hemostemix.com.

Story continues

Contact: Thomas Smeenk, President, CEO & Founder905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions; or, may include statements and words that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on the reasonable assumptions of Management, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Management on the date such statements are made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Company's ability to fund operations and access the capital required to continue operations, the Company's stage of development, the ability to complete its current clinical trial, complete its futility analysis and the results of such, future clinical trials and results, long-term capital requirements and future developments in the Company's markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Company's operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Additional information identifying risks and uncertainties are contained in the Company's filing with the Canadian securities regulators, which filings are available at http://www.sedar.com.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/54700

See the article here:
Hemostemix Announces the Appointment of Timothy Chang to Board of Advisors - Yahoo Finance

A leader in treating haematological cancers – The Business Times

By adminApril 22, 2020Stem Cell Treatment

Wed, Apr 22, 2020 - 5:50 AM

PATIENTS from around the world have benefited from Parkway Cancer Centre's (PCC) comprehensive and holistic approach to treating haematological cancers, or cancers of the blood. The field of haematology covers a broad spectrum of blood disorders, with the World Health Organization estimating that there are as many as 72 types and sub-types of this form of cancer.

With one of the largest and most experienced teams of haematologists in Singapore - comprising three oncologists and one paediatric oncologist - PCC is able to offer specialised care for the management of a wide range of adult and childhood conditions, including leukaemia and lymphoma, among many others.

Significantly, this core group of haematologists is supported by dedicated transplant physicians, oncology and transplant nurses, transplant coordinators, counsellors and allied health professionals. The breadth of its resources allows PCC to adopt a holistic approach to care that enhances the patient journey and results in better healthcare outcomes.

Treatments provided by the haematology oncology team range from intensive chemotherapy, molecular targeted therapy and novel immunotherapy to stem cell transplantation. For each patient, the team devises a personalised treatment plan that aims to optimise clinical outcomes.

"In all diseases, especially cancers, it is important to be able to see patients as individuals in need of treatment that extends beyond specialised investigations and medications. This is best achieved by a multidisciplinary team approach that identifies the patient's medical and emotional needs, preferences and values," said Dr Colin Phipps Diong, Senior Consultant, Haematology Oncology at PCC.

"We are able to draw on the collective expertise of our multidisciplinary team and use our knowledge bank of experience gleaned from successfully treating some of the most challenging and complex cases. Being at the fore of medical advancements gives us the capability and confidence to provide our patients with current treatment options," he added.

A Pioneer in Bone Marrow Transplantation

Reflecting the depth of its expertise in this specialised field, PCC is the only private healthcare provider that offers a comprehensive adult and paediatric blood and bone marrow transplant programme. Indeed, the centre's haematology team performed the first bone marrow transplant in a private hospital setting in Singapore more than two decades ago.

Bone marrow transplantation, known formally as haematopoietic stem cell transplantation, is a specialised procedure which has proven to be effective in treating many types of cancers, as well as blood and autoimmune disorders such as leukaemia and lymphoma.

Since the 1950s, more than one million transplants have been performed globally, with the success of the procedure largely dependent on the skill and experience of the multidisciplinary transplant team. Transplant specialists at the PCC Haematology and Stem Cell Transplant Centre perform transplants from family members, unrelated donors, and cord blood, for a range of conditions, both non-malignant (thalassaemia, aplastic anaemia) and malignant (acute leukaemias, lymphoma, myeloma).

These specialists have extensive experience in bone marrow transplants in both adult and paediatric patients, having trained and worked at some of the leading transplant centres around the world.

Even though stem cell transplantation has been proven to save lives, there are still risks associated with the procedure. At PCC, these risks are clearly explained to the patients and caregivers before they consent to the procedure. "Complex treatment decisions are regularly discussed between the transplant physicians to formulate an optimal plan for our patients," explained Dr Diong.

The transplantation process involves several important stages: Conditioning where the patient receives chemotherapy and/or radiation to kill the diseased cells and to change the immune system; infusion of healthy stem cells into the body to replace the damaged cells; engraftment, when the transplanted stem cells begin to grow and produce healthy red and white blood cells and platelets over the course of two to four weeks; and post-transplant recovery where the "new" immune system matures and develops the ability to fight infections and blood cancer cells.

Looking ahead, PCC will continue to develop its expertise and services to stay ahead of the curve in treating haematological cancers. "We are always looking ahead. It is important that we build our team further to broaden our regional footprint and expand services to bring our patients access to cutting-edge science like CAR T-cell therapies," said Dr Diong.

"In this regard, we strive to develop services, infrastructure, and facilities that are internationally accredited together with our partners in Parkway. At the same time we will continue to work with all stakeholders to ensure that cost is manageable and more patients have access to our transplant services."

PCC's holistic philosophy

More:
A leader in treating haematological cancers - The Business Times

Sangamo taps Mogrify for off-the-shelf CAR-Treg project – FierceBiotech

By adminApril 22, 2020Stem Cell Treatment

Sangamo Therapeutics has struck a deal with Mogrify to gain access to a source of cells for use in its allogeneic CAR-Treg therapies. The agreement sees Sangamo pay an upfront fee to get Mogrify to apply its direct cell conversion technology to the generation of regulatory T cells.

Ready access to sources of cells has emerged as a key area of focus for developers of off-the-shelf cell therapies, leading to deals such as Allogenes alliance with Notch Therapeutics. That deal, like other moves by allogeneic cell therapy players, reflected a desire to replace the finite donated T cells used in early off-the-shelf prospects with renewable, more scalable sources of starting materials.

Sangamo has identified Mogrify as a provider of such materials. Mogrify put itself on the map early last year when Darrin Disley, the former leader of Horizon Discovery, joined the startup as CEO and invested in its seed round. Months later, Mogrify raised a $16 million series A round.

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

Mogrify attracted the interest of Disley, Sangamo and an investor syndicate led by Ahren Innovation Capital on the strength of its technology for converting one human cell type into another human cell type. In the case of the Sangamo deal, Mogrify will use the platform to convert induced pluripotent stem cells and embryonic stem cells into regulatory T cells.

RELATED:Bristol Myers' Juno unit enlists Oxford BioMedica for CAR-T work

The agreement with Sangamo tasks Mogrify with handling the discovery and optimization of the cell conversion technology. Sangamo will have exclusive rights to use the technology to generate Tregs. By applying its ZFP gene engineering technology to the Tregs, Sangamo plans to develop allogeneic cell therapies for use in the treatment of inflammatory and autoimmune diseases.

Sangamo is paying an upfront fee of undisclosed size to work with Mogrify. As programs based on the Tregs advance, Mogrify is in line to receive development and regulatory milestones, plus payments linked to product sales.

SPECIAL REPORT:Top biotech money raisers of 2019

News of the deal comes months after Sangamo got authorization in the U.K. to run a phase 1/2 trial of an autologous CAR-Treg cell therapy, TX200, in kidney transplant patients. Partnering with Mogrify will support Sangamos efforts to get allogeneic cell therapies into the clinic, building on its work with Kite Pharma to apply its technology to off-the-shelf cancer treatments such as CD19 CAR-T prospect KITE-037.

Having formed the pact with Sangamo, Mogrify now has two commercial deals with U.S. biopharma companies. The deals will provide Mogrify with a source of money as it works on internal cell therapy candidates in disease areas including musculoskeletal, autoimmune and cancer.

View original post here:
Sangamo taps Mogrify for off-the-shelf CAR-Treg project - FierceBiotech

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,…

By adminApril 22, 2020Stem Cell Treatment

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market is expected to grow from US$ XXBn in 2018 to USD XX Bn by 2026, at a CAGR of 6.1% during the forecast period.

Platelet-rich plasma (PRP) a new biotechnology, is the product of a heightened interest in cell-based therapy and tissue engineering. This therapy is defined as an autologous preparation of plasma with concentrated platelets.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment MarketGlobal Atomic Force Microscopes Market Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Drivers and RestrainsFactors contributing to the growth of this market include rise in disease awareness, treatment rate, and growing adoption of novel treatment therapies providing positive patient outcome. Moreover, lower incidences of negative side effects of this therapy are anticipated to fuel demand for platelet rich plasma (PRP) and stem cell therapy.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/36142

Treatment options for androgenic alopecia are limited and include topical minoxidil and oral finasteride (FDA approved) alone or in combination. Several reported side effects such as headache and increase in body hair are there for minoxidil whereas loss of libido has been reported with oral finasteride are considered to be major restraint to the global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market.

Hair loss is one of the significant factors that will foster the global hair transplant market growth over the projection period. Increasing patient pool in developing countries significant success rate and hair transplant procedures coupled with innovative technologies also help hair transplant market to grow seamlessly in the near future.

Advance treatments for alopecia are enhanced by dermatologists and patients over regular medications, for example, corticosteroids. More prominent inclination for these treatments emerges from proficient and quicker hair regrowth when contrasted with other corticosteroid medications. Furthermore, simplicity of organization of these novel treatments is anticipated to boost the global market.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by key segments

The stem cell therapy segment has been further classified into bone marrow treatment and adipose treatment. The dermatology clinics segment accounted for 88% of the total market revenue in 2018, owing to its lower therapy cost as compared to hospitals.

About 45% men and 35% women develop androgenic alopecia by 60, which is the highest among all the types of alopecia in the year 2018. A study published in the International Journal of Womens Dermatology in 2019 revealed that the use of PRP to treat androgenic alopecia is promising due to its autologous nature, minimal invasiveness, lack of major side effects, and low cost compared to hair restoration surgery.

Global Systemic Inflammatory Response Syndrome Treatment Market Regional AnalysisNorth America is anticipated to held leading position for global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market . In 2018, XX% of women suffer from androgenetic alopecia in North America. This has led the country to dominate the platelet rich plasma & stem cell alopecia treatment market in North America. The market in Asia Pacific is projected to expand at a significantly high CAGR during the forecast period, owing to the emergence of strong local manufacturers offering various technological advancements for platelet rich plasma & stem cell alopecia treatment at lower prices and increase in awareness among people about these treatment methods. Additionally, highest application of PRP for the treatment of alopecia has been observed in the past few years. This is likely to fuel the market in the region. Furthermore, technological advances and huge numbers of investments in Platelet Rich Plasma Therapies by key players are likely to fuel the global market in the emerging regions such as in china and India.

The objective of the report is to present comprehensive analysis of Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market dynamics, structure by analyzing the market segments, and project the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market size. Clear representation of competitive analysis of key players by Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market make the report investors guide.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/36142

Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market, by Treatment

Platelet Rich Plasma Therapies Stem Cell TherapyGlobal Platelet Rich Plasma & Stem Cell Alopecia Treatment Market, by Indication

Androgenic Alopecia Congenital Alopecia Cicatricial or Scarring AlopeciaGlobal Platelet Rich Plasma & Stem Cell Alopecia Treatment Market, by Type

Men womenKey players operating on Global Platelet Rich Plasma & Stem Cell Alopecia Treatment Market

Kerastem Eclipse Regen Lab SA Restore Hair Replicel LifeScience Histogen Inc. Glofinn Oy Orange County Hair Restoration Center, Hair Sciences Center of Colorado, Anderson Center for Hair, Evolution Hair Loss Institute, Savola Aesthetic Dermatology Center, Virginia Surgical Center, Hair Transplant Institute of Miami, Colorado Surgical Center & Hair Institute.

MAJOR TOC OF THE REPORT

Chapter One: Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Competition, by Players

Chapter Four: Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size by Regions

Chapter Five: North America Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Countries

Chapter Six: Europe Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Countries

Chapter Seven: Asia-Pacific Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Countries

Chapter Eight: South America Platelet Rich Plasma and Stem Cell Alopecia Treatment Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Platelet Rich Plasma and Stem Cell Alopecia Treatment by Countries

Chapter Ten: Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segment by Type

Chapter Eleven: Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Segment by Application

Chapter Twelve: Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Report at:https://www.maximizemarketresearch.com/market-report/global-platelet-rich-plasma-and-stem-cell-alopecia-treatment-market/36142/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Go here to see the original:
Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Industry Analysis and Forecast (2019-2026): By indication type, treatment type,...

Coronavirus Q&A: Dr. Camillo Ricordi Gives Update On Trials Of Stem Cell Treatment For Most Severe COVID-19 Cases – CBS Miami

By adminApril 22, 2020Stell Cell Research

MIAMI (CBSMiami) A team of doctors at the University of Miami is working on what could be groundbreaking therapy for treating some COVID-19 patients.

With a focus on those suffering with severe lung inflammation, theyre using the umbilical system cells to treat patients.

For an update on how its progressing, Dr. Camillo Ricordi, a University of Miami professor and stem cell therapy researcher, joined Eliott Rodriguez and Rudabeh Shahbazi via Skype.

Q: This therapy is building off a 10-patient study in China and the results of that study are limited. So what information gave you hope that this would work on a broad scale?

A: Well, the information from this initial study have been incredibly encouraging. The editor in chief of the journal that did editorial on the paper presented commented as extraordinary results, but that need to be validated by law by lots of clinical trials. So were happy that FDA approved us to do such clinical trial at the University of Miami. And the nice thing is that well have the results in a very short time because these cells is like injecting anatomy of cells, 200 million cells, into those that will be fighting the complication of the infection and will know within weeks the there is a positive effect.

Q: How many patients are in the trial? When did you start? Have you seen any results so far?

A: We did. We have 24 patients in this initial trials. We didnt start the first patient, there have been only patients that are on compassionate release so far. And the initial results are coming from China and Israel. But we are ready to go. We have the terms the six doses already ready to be delivered and other 25 doses are ready to follow. So we have over as far as cell supply for the entire clinical trial, and we hope to have results very soon.

Q: So for the layman like us, can you explain how, why the stem cells infused in a vein end up in a lung?

A: Yeah, actually, this is a nice feature because when we do these trials, I directed Diabetes Research Institute at the University of Miami, so, traditionally, we did this trial for type 1 diabetes or for kidney disease. But in this case, when you inject the cells IV, intravenously, the first filter that is the lungs. So naturally the cells are trapped by the lungs as much as 95%. So in the case of targeting the pancreas or the kidney, you have to do an interventional radiology procedure to put a catheter in there that goes to these organs. But when you target the lung, this is a natural way of delivery and these cells form naturally to the lung. In addition, the cells sense inflammation and tissue injury, and hone, they go targeting specifically the site of tissue injury and inflammation. So in this case is even more relevant that in a simple intravenous, like a blood transfusion, will exactly target the lung, that is the organ that we want to treat

Q: How long do you expect to have to wait before you know if this was working?

A: Well, we know from the radiologic examination of the lungs from the studies in China, for example, that within days a resolution of the lung pathology.

Q: What is the typical recovery rate for COVID patients who have been put on a ventilator and is that meant to treat patients before they get to that critical stage?

A: Well, the typical recovery rate that we expect with this treatment is within a week we should know. So this is not a trial that we are required, like months or years of follow up to see if there is a beneficial effect or not. We are confident that within days or a week you will know if this is working or not as soon as we start.

Q: Is this is therapy meant to complement other forms of therapy?

A: I think it will definitely be used as a combination therapy. We dont exclude any other therapy as part of the combination therapy. With another agent that may help fight this is immune reaction, this pro-inflammatory reaction and also the problem that you see in micro-thromboembolism and the coagulation problem that you see in these patients. So I think is in a way is a unique therapy because its not just for COVID-19, but its for any virus targeting the lung with this massive reaction. So it will be something that we are planning in the future to create the repository for rapid intervention and integrated response to any pandemic or a situation in which you have an emergency that you need to treat an injury to the lung of such dimension. But in the meantime, when there is not a pandemic situation, you can use these cells. We have trials ongoing that has been authorized by the FDA for type 1 diabetes, Alzheimer, for kidney disease. So its a cell type that can be used in many other situations to start normal organ function, not just COVID-19.

Q: If this succeeds, how big of a deal is it?

A: If this succeeds, it will be a way to treat the severe cases of COVID-19 while we wait for a vaccine. But also to have a repository of cells that will be able to treat any other possible pandemic or epidemic where the lung will be a target of the viral attack. In this case, you have an army of cells that are ready to be used and fight this viral infection and all the consequences that can induce in the lungs.

RELATED:Current Curfews In South FloridaDrive-Through Testing LocationsTrack The Spread Of The Coronavirus In Real TimeHow To Make Your Own Face Mask

See more here:
Coronavirus Q&A: Dr. Camillo Ricordi Gives Update On Trials Of Stem Cell Treatment For Most Severe COVID-19 Cases - CBS Miami

Vitro Biopharma Submits IND Application to FDA for AlloRx Stem Cell(R) Therapy of COVID-19 – Yahoo Finance

By adminApril 22, 2020Stell Cell Research

GOLDEN, CO / ACCESSWIRE / April 21, 2020 / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma announced the filing an investigational new drug (IND) application with the FDA for clinical use of AlloRx Stem Cells in the treatment of COVID-19 patients in the US. Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging safety and efficacy results. Seventeen critically ill patients treated with umbilical cord-derived stem cells that are comparable to AlloRx Stem Cells, responded quickly by no longer requiring ventilator assisted breathing and were discharged. Also, the Israeli firm Pluristem recently reported recovery in six patients treated with similar stem cells derived from the human placenta. Together with prior safety studies conducted by Vitro Biopharma and others, there is a strong & compelling argument to allow clinical testing of AlloRx Stem Cells for COVID-19 infections in our proposed Phase I study.

Dr. Jim Musick, Ph.D., CEO said, "We are very pleased to have submitted our IND using our expanded regulatory team, including a renown regulatory expert in FDA clinical trial management. We are establishing strong communication channels with FDA officials to facilitate and expedite review of our application as well as subsequent steps to gain full FDA approval of AlloRx Stem Cells. Several clinical centers have expressed interest in our stem cell therapy. We are also pursuing other avenues for compassionate use and the COVID-19 Treatment Plan Acceleration Program. We are confident that our therapy is safe & effective based on our prior studies and those of others. MSCs block the cytokine storm that occurs in COVID-19 patients in acute respiratory distress through their powerful anti-inflammatory effects. The cytokine storm leads to the need for assisted breathing by ventilators, transfer to ICU and tremendous burdens on the US health care system. It is important to note that AlloRx Stem Cells are therapy for other viral attacks including influenza since stem cells block acute respiratory distress and damage to other major organs including cardiovascular, pulmonary and renal systems. AlloRx Stem Cells are very likely to assist in recovery from failure of various organ systems in COVID-19 survivors"

About Vitro Biopharma:

Vitro Biopharma, for over 10 years, has supplied major biopharmaceutical firms, elite university laboratories and clinical trials worldwide with Mesenchymal Stem Cells, MSC-Grow Brand of cell culture media, various stem cell derivatives and stem cell-derived differentiated cells. We also supply primary fibroblast cells and an expanding line of cancer-associated fibroblasts (CAFs) from various tumors including lung, breast, melanoma, pancreatic and colorectal tissues. Our CAFs are purchased by major pharmaceutical and biopharmaceutical firms to advance immunotherapy of cancer.

Out of years of research, we developed our patent-pending and proprietary line of umbilical cord derived stem cells AlloRx Stem Cells now being used in offshore regenerative medicine clinical trials. Our stem cells are used in regenerative medicine clinical trials with our partner in the Cayman Islands http://www.DVCStem.com. We have a recently approved clinical trial using our AlloRx Stem Cells to treat musculoskeletal conditions at The Medical Pavilion of the Bahamas http://www.tmp-bahamas.com in Nassau.

Vitro Biopharma has a proprietary and scalable manufacturing platform to provide stem cell therapies to critically ill Coronavirus patients and other conditions including multiple sclerosis, OA, Chrohn's disease and numerous medical conditions that are under-treated by the current standard of care. Our cGMP manufacturing is ISO9001, ISO13485 certified and we are FDA registered. Our stem cells have been shown to be safe and effective in Phase I clinical trials.

CONTACT:

Dr. James MusickChief Executive OfficerVitro Biopharma(303) 550-2778 E-mail: jim@vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures. Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements. Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

Story continues

See the original post here:
Vitro Biopharma Submits IND Application to FDA for AlloRx Stem Cell(R) Therapy of COVID-19 - Yahoo Finance

Live Cell Imaging Market in North America region at a CAGR of 8.9% according to a new research report – WhaTech Technology and Markets News

By adminApril 22, 2020Stell Cell Research

The Global Live Cell Imaging market to grow from USD 2.9 billion by 2023 from an estimated USD 1.9 billion in 2018, at a CAGR of 8.9%

The growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, and the growth in funding for research are the major factors driving the growth of the global live cell imaging market. However, factors such as the high cost of high-content screening systems and the shortage of skilled professionals are expected to restrain the growth of this market during the forecast period.

How much is the Live Cell Imaging Market worth?

MarketsandMarketsforecasts theLive Cell Imaging marketto grow from USD 2.9 billion by 2023 from an estimated USD 1.9 billion in 2018, at a CAGR of 8.9% during the forecast period. Factors such as the high cost of high-content screening systems and the shortage of skilled professionals are expected to restrain the growth of this market during the forecast period.

The globalLive Cell Imaging marketis segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. In 2018, North America accounted for the largest share of this market majorly due to the growth in biomedical research in the US, rising preclinical activities by CROs and pharmaceutical companies, and growing stem cell research in Canada.

The instruments segment accounted for the largest share of the market in 2018

On the basis of product and service, the global live cell imaging market is segmented into instruments, consumables, software, and services. In 2018, the instruments segment accounted for the largest share of the live cell imaging market.

Factors such as the launch of new and advanced instruments, increasing incidence of diseases, and rising government initiatives and awareness programs for promoting cell-based research are the major factors driving the demand for live cell imaging instruments.

The academic & research institutes segment is expected to grow at the highest CAGR during the forecast period

On the basis of end user, the live cell imaging market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations (CROs). The academic & research institutes segment is expected to grow at a higher CAGR during the forecast period.

The high growth in this segment can be attributed to the increasing focusing of academic and research institutes on strengthening their own drug discovery research programs coupled with rising government funding to support research and advancing scientific goals.

Download PDF Brochure atwww.marketsandmarkets.com/pdfdown=163914483

The stem cells segment is expected to grow at the fastest rate during the forecast period

On the basis of application, the live cell imaging market is segmented into cell biology, stem cells, developmental biology, and drug discovery. The stem cells segment is expected to grow at the highest CAGR during the forecast owing to the increasing stem cell research activity and investments.

North America to account for the largest market size during the forecast period.

North America is the major revenue generating region in the live cell imaging market. The live cell imaging market in the region is driven by the availability of government funding for life science research, drug development regulations, advances in live cell imaging techniques, growth in the biotechnology and pharmaceutical industries, and the rising incidence of cancer.

Report:www.marketsandmarkets.com/request=163914483

Who are the leading vendors operating in Live Cell Imaging Market?

Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc.

(US), Sartorius AG (Germany), BioTek Instruments (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), and NanoEnTek Inc.

(Korea).

Danaher dominated the live cell imaging market in 2017. The company is a global leader in live cell imaging and has been operating in the market for about 50 years.

Innovation is the prime strength of the company, on the basis of which, Danaher has been able to expand its product portfolio, enter new markets, and build a better network for increasing its customer base.

Report: http://www.marketsandmarkets.com/speakto=163914483

This email address is being protected from spambots. You need JavaScript enabled to view it.

Stem Cell Cartilage Regeneration Market Share Analysis and Research Report by 2025 – Express Journal

By adminApril 22, 2020Stell Cell Research

Growth Analysis Report onStem Cell Cartilage Regeneration Market size | Industry Segment by Applications (Hyaline Cartilage, Fibrocartilage and Other), by Type (Cell Based Approaches and Non-cell Based Approaches), Regional Outlook, Market Demand, Latest Trends, Stem Cell Cartilage Regeneration Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report titled, Stem Cell Cartilage Regeneration market has adopted an organized way to evaluate the dynamics of the overall market. It provides a comprehensive Stem Cell Cartilage Regeneration market analysis comprising of a top-to-bottom research on the market dynamics, including Stem Cell Cartilage Regeneration market growth drivers, challenges, threats, and potential growth opportunities, with a key focus on not only the global market but also the regional market. In a chapter-wise format, the Stem Cell Cartilage Regeneration market share report evaluated the global supply and demand trends in the market, including the significant insights and graphical representation.

The report provides data taking into attention the latest advancements in the global Stem Cell Cartilage Regeneration Market while appraising the impact in the Stem Cell Cartilage Regeneration market of the most important players in the near future.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/59027

Some of the Major Stem Cell Cartilage Regeneration Market Players Are:

Brief of the competitive landscape

The Stem Cell Cartilage Regeneration market report consists of a brief of the competitive terrain of this industry. The study specifies an Stem Cell Cartilage Regeneration Market analysis of the competitive scope in the competitive landscape. Data related to the participants of the industry along with its current share in the Stem Cell Cartilage Regeneration market, area served as well as production sites is involved in the report.

Along with that, details regarding companys product portfolio, products application areas, as well as features of the product has been presented in the research study of Stem Cell Cartilage Regeneration Market report. Information about the profiles of the companies as well as data related to their profit margins and models is also induced in the report.

Stem Cell Cartilage Regeneration Market Outlook by Applications:

Stem Cell Cartilage Regeneration Market Statistics by Types:

The research report studies the historical, present, and future performance of the Stem Cell Cartilage Regeneration market. The report further evaluates the present competitive landscape, prevalent business models and the possible advancements in offerings by significant players of Stem Cell Cartilage Regeneration market in the up-coming years.

Key highlights of the Stem Cell Cartilage Regeneration market report:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/59027

Global Tissue Engineering Market (2019 to 2027) – Analysis and Forecasts by Tissue Type, Application and Geography – ResearchAndMarkets.com – Business…

By adminApril 22, 2020Stell Cell Research

DUBLIN--(BUSINESS WIRE)--The "Tissue Engineering Market to 2027 - Global Analysis and Forecasts by Tissue Type; Application, and Geography" report has been added to ResearchAndMarkets.com's offering.

The tissue engineering market was valued at US$ 9,529.21 million in 2019 and is expected to grow at a CAGR of 13.5% from 2020 to 2027 to reach US$ 25,586.55 million by 2027.

Driving factors of the tissue engineering market are increasing incidences of chronic diseases, road accidents, and trauma injuries, as well as technological advancements in the field of 3D tissue engineering. However, high cost of treatments related to tissue engineering is expected to restrain the growth of the market during the forecast period.

Rising incidence of chronic diseases and growing number of trauma injuries and road accidents are prime factors contributing to the growth of the market for advanced treatment procedures, such as tissue engineering. Road accidents are among the major fatalities worldwide as they cause serious injuries to bones and organs. As per the WHO, ~20-50 million people get injured every year in road accidents. Tissue engineering offers alternatives to surgical reconstruction, transplantation, and mechanical device instruction to repair damaged tissues. The tissue engineering market is mainly driven by a continuous need for effective regenerative treatments to treat increasing cases of diabetes, obesity, and other disorders caused by lifestyle changes; growing base of elderly people; and rising number of trauma cases.

Moreover, the increasing government funding for research activities is expected to enhance the growth of the tissue engineering market. For instance, as per the National Institutes of Health (NIH) funding study in the US, the research studies pertaining to stem cell and regenerative medicines received funding of USD 1.8 billion and USD 1.0 billion, respectively, in 2018.

The global tissue engineering market is segmented into material type and application. The tissue engineering market, by material type, is further segmented into synthetic material, biologically derived materials, and others. The biologically derived materials segment held the largest share of the market in 2019, whereas the segment synthetic materials is anticipated to register the highest CAGR in the market during the forecast period. Based on application, the market is further segmented into orthopedic, musculoskeletal, and spine; neurology; cardiology and vascular; skin; and others. The orthopedic, musculoskeletal, and spine segment held the largest share of the market in 2019, whereas the skin segment is estimated to register the highest CAGR in the market during the forecast period.

Some of the essential primary and secondary sources included in the report are Centers for Disease Control and Prevention, Food and Drug Administration, and Organization for Economic Co-operation and Development.

Reasons to Buy:

Market Dynamics

Drivers

Restraints

Opportunities

Trends

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/izu0dk

Stem Cell Market Competitive Insights and Research 2020 Cole Reports – Cole of Duty

By adminApril 22, 2020Stell Cell Research

Global Stem Cell Market Research Report published bymarket insight reportsexplores the current outlook in global and key regions from the perspective of Major Players, Countries, Product types and end industries. This report analyzes top players in the global market, and divides the Market into several parameters.

This Stem Cell Market research report identifies the competitive landscape of industries to understand the competition at International level. This report study describes the projected growth of the global market for approaching years from 2019 to 2027. This research report has been aggregated on the basis of static and dynamic aspects of the businesses.

Click Here to Get Sample PDF Copy of Latest Research on Stem CellMarket 2019:

https://www.marketinsightsreports.com/reports/03121899392/global-stem-cell-market-research-report-2015-2027-of-major-types-applications-and-competitive-vendors-in-top-regions-and-countries/inquiry?Mode=18

The prominent players in the Global Stem Cell Market:

Cyagen Biosciences, Cellular Biomedicine, Xian International Medical Investment Co., Ltd., Guanhao Biotech Co.,Ltd., Sichuan Languang Development Co.,Ltd., Shire Life Group, Anhui Lejin Health Technology Co., Ltd., Stemedica, Hebei Life Origin Biotechnology Co., Ltd., Zhongyuan Concord Cell Genetic Engineering Co., Ltd., Cordlife and Others.

It further provides the profile reviews of the leading participants, their overall market shares in the global market, business strategies they have adopted, and the latest developments in their respective business in a bid to enhance the decision-making capability of the readers.

The Stem Cell market can be divided based on product types and Its sub-type, major applications and Third Party usage area, and important regions.

This report segments the Global Stem Cell Market on the basis ofTypesare:

Allogenic SCsAutologous SCs

On the basis ofApplication,the Global Stem Cell Market is segmented into:

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOthers

SPECIAL OFFER: AVAIL UPTO 20% DISCOUNT ON THIS REPORT:

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Stem Cell Market these regions, from 2019 to 2027 (forecast), coveringNorth America, Europe, China, Japan, Southeast Asia, India, North America(USA, Canada and Mexico)Europe(Germany, France, UK, Russia and Italy)AsiaPacific(China, Japan, Korea, India and Southeast).

Detailed overview of Stem Cell Market Changing market dynamics of the industry In-depth market segmentation by Type, Application etc. Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape of Stem Cell Market Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth

The research includes historic data from 2014 to 2019 and forecasts until 2027 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts and stakeholders looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Finally, the Stem Cell market report offers a complete and detailed study of global Stem Cell market by using numerous analytical tools and models such as SWOT analysis, investment return analysis, and porters five forces analysis which are useful for beginners to access the upcoming opportunities. After exploring the market insights through primary and secondary research methodologies, if anything is required except than this, market insight reports will provide customization as per specific demands.

Click the link to Purchase This Full Report @:

https://www.marketinsightsreports.com/report/purchase/03121899392?mode=su?Mode=18

We also offer customization on reports based on specific client requirement:

1- Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis ofany 5 key market players.

3-Free40 analyst hoursto cover any other data points.

Note: All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Read this article:
Stem Cell Market Competitive Insights and Research 2020 Cole Reports - Cole of Duty